The inhibition of IDO activity could improve insulin sensitivity, maintain the intestinal mucosal barrier, reduce endotoxemia and chronic inflammation, and regulate lipid metabolism in both liver and adipose tissues (50). The gene discussed is INS; the disease is serum lipopolysaccharide activity.